Stocktoria
Arcutis Biotherapeutics, Inc. ARQT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-01-31
Arcutis Biotherapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -3.3% | -65.3% | -404.5% | -8183.0% | — |
| Net margin | -4.3% | -71.3% | -439.8% | -8449.8% | — |
| FCF margin | -1.7% | -57.1% | -415.2% | -7000.8% | — |
| Return on assets | -3.7% | -40.1% | -76.8% | -69.3% | -50.6% |
| Return on equity | -8.5% | -88.9% | -295.6% | -148.6% | -69.3% |
| Debt / equity | 0.58× | 0.68× | 2.28× | 0.94× | 0.24× |
| Current ratio | 3.17 | 4.15 | 7.08 | 11.57 | 12.09 |
| Revenue growth | 91.3% | 229.7% | 1517.1% | — | — |
Source: SEC EDGAR filings · CIK 0001787306 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.